| [1] |
Pop LG, Bacalbasa N, Suciu ID, et al. Tuberculosis in pregnancy. J Med Life, 2021, 14(2):165-169. doi:10.25122/jml-2021-0001.
doi: 10.25122/jml-2021-0001
pmid: 34104238
|
| [2] |
Peng W, Yang J, Liu E. Analysis of 170 cases of congenital TB reported in the literature between 1946 and 2009. Pediatr Pulmonol, 2011, 46(12):1215-1224. doi:10.1002/ppul.21490.
doi: 10.1002/ppul.21490
URL
|
| [3] |
夏世文, 彭斯聪. 新生儿先天性结核的诊断与治疗. 中华实用儿科临床杂志, 2020, 35(23):1766-1769. doi:10.3760/cma.j.cn101070-20201117-01768.
doi: 10.3760/cma.j.cn101070-20201117-01768
|
| [4] |
邵肖梅, 叶鸿瑁, 丘小汕. 实用新生儿学. 5版. 北京: 人民卫生出版社, 2019:528-529.
|
| [5] |
Lei Q, Wang H, Zhao Y, et al. Determinants of serum concentration of first-line anti-tuberculosis drugs from China. Medicine (Baltimore), 2019, 98(41):e17523. doi:10.1097/MD.0000000000017523.
doi: 10.1097/MD.0000000000017523
URL
|
| [6] |
Mittal H, Das S, Faridi MM. Management of newborn infant born to mother suffering from tuberculosis: current recommendations & gaps in knowledge. Indian J Med Res, 2014, 140(1):32-39.
pmid: 25222775
|
| [7] |
Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child, 2005, 90(6):614-618. doi:10.1136/adc.2004.052175.
doi: 10.1136/adc.2004.052175
pmid: 15908628
|
| [8] |
Zhu R, Kiser JJ, Seifart HI, et al. The pharmacogenetics of NAT 2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol, 2012, 52(4):511-519. doi:10.1177/0091270011402826.
doi: 10.1177/0091270011402826
URL
|
| [9] |
Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother, 2011, 55(12):5560-5567. doi:10.1128/AAC.05429-11.
doi: 10.1128/AAC.05429-11
pmid: 21968358
|
| [10] |
Zuur MA, Bolhuis MS, Anthony R, et al. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol, 2016, 12(5):509-521. doi:10.1517/17425255.2016.1162785.
doi: 10.1517/17425255.2016.1162785
URL
|
| [11] |
World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva: World Health Organization, 2014.
|
| [12] |
Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob Agents Chemother, 2016, 25;60(4):2171-2179. doi:10.1128/AAC.02600-15.
doi: 10.1128/AAC.02600-15
|
| [13] |
Wang P, Pradhan K, Zhong XB, et al. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B, 2016, 6(5):384-392. doi:10.1016/j.apsb.2016.07.014.
doi: 10.1016/j.apsb.2016.07.014
pmid: 27709007
|
| [14] |
Thomas L, Raju AP, Chaithra, et al. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. Eur J Clin Pharmacol, 2022, 78(10):1535-1553. doi:10.1007/s00228-022-03362-7.
doi: 10.1007/s00228-022-03362-7
pmid: 35852584
|
| [15] |
Zhu R, Kiser JJ, Seifart HI, et al. The pharmacogenetics of NAT 2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol, 2012, 52(4):511-519. doi:10.1177/0091270011402826.
doi: 10.1177/0091270011402826
URL
|
| [16] |
McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis, 2009, 48(11):1547-1553. doi:10.1086/598192.
doi: 10.1086/598192
pmid: 19392636
|
京公安网备11010202008787号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
